Aim Immunotech Story

<div class='circular--portrait' style='background:#000000;color: #f2f2f2;font-size:4em;'>AI</div>
AIM -- USA Stock  

USD 1.98  0.12  6.45%

Lets try to summarize the odds of Aim Immunotech to fully recover from the new pull down as its shares went up 7.41%. The company's current daily volatility is 5.74 percent, with a beta of -0.27 and an alpha of -0.27 over DOW. As many baby boomers are still indifferent towards pharmaceutical products, it makes sense to summarize Aim Immunotech. We will look into some reasons why it is still possible for Aim Immunotech to maintain above-average margins while minimizing volatility.
Published over two weeks ago
View all stories for Aim Immunotech | View All Stories
Should you exit Aim Immunotech after the new volatility pull down?
Aim Immunotech has about 35 M in cash with (9.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.88. We provide trade advice to complement the prevailing expert consensus on Aim Immunotech. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
Investing in Aim Immunotech, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Aim Immunotech along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.

How important is Aim Immunotech's Liquidity

Aim Immunotech financial leverage refers to using borrowed capital as a funding source to finance Aim Immunotech ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Aim Immunotech financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Aim Immunotech's total debt and its cash.

How Aim Immunotech utilizes its cash?

To perform a cash flow analysis of Aim Immunotech, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Aim Immunotech is receiving and how much cash it distributes out in a given period. The Aim Immunotech cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Aim Immunotech Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (9.78 Million)

Aim Immunotech Correlation with Peers

Investors in Aim Immunotech can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Aim Immunotech. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Aim Immunotech and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Aim Immunotech is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage. Please check volatility of Aim Immunotech for more details

Breaking down the case for Aim Immunotech

Aim Immunotech secures Sharpe Ratio (or Efficiency) of -0.0317, which signifies that the company had -0.0317% of return per unit of risk over the last month. Macroaxis standpoint towards foreseeing the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and technical indicators. Aim Immunotech exposes twenty-eight different technical indicators, which can help you to evaluate volatility that cannot be diversified away. Please be advised to confirm Aim Immunotech mean deviation of 3.83, and Risk Adjusted Performance of (0.05) to double-check the risk estimate we provide.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Are Aim Immunotech technical ratios showing a turnaround?

Aim Immunotech new maximum drawdown upsurges over 35.14. Aim Immunotech exhibits very low volatility with skewness of 1.38 and kurtosis of 5.45. However, we advise investors to further study Aim Immunotech technical indicators to make sure all market info is available and is reliable.

The Current Takeaway on Aim Immunotech Investment

While some other entities in the biotechnology industry are either recovering or due for a correction, Aim Immunotech may not be performing as strong as the other in terms of long-term growth potentials. To conclude, as of the 14th of November 2020, we believe that Aim Immunotech is currently undervalued with quite high odds of financial distress in the next two years. However, our ongoing 30 days buy-hold-sell recommendation on the company is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Aim Immunotech. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com